Pregledni rad

DO WE KNOW ALL EFFECTS OF HEPARINS IN HEMODIALYZED PATIENTS?

MILENKA ŠAIN ; Klinički bolnički centar Split, Klinički odjel za nefrologiju i dijalizu, Medicinski fakultet, Sveučilište u Splitu, Split, Hrvatska
DRAGAN LJUTIć ; Klinički bolnički centar Split, Klinički odjel za nefrologiju i dijalizu, Medicinski fakultet, Sveučilište u Splitu, Split, Hrvatska
VEDRAN KOVAčIć ; Klinički bolnički centar Split, Klinički odjel za nefrologiju i dijalizu, Medicinski fakultet, Sveučilište u Splitu, Split, Hrvatska
JOSIPA RADIć ; Klinički bolnički centar Split, Klinički odjel za nefrologiju i dijalizu, Medicinski fakultet, Sveučilište u Splitu, Split, Hrvatska
IVO JELIčIć ; Klinički bolnički centar Split, Klinički odjel za nefrologiju i dijalizu, Medicinski fakultet, Sveučilište u Splitu, Split, Hrvatska

Sažetak

Anticoagulation with heparins during hemodialysis (HD) is aimed at preventing the activation of coagulation in the extracorporeal circuit. As HD patients are exposed to unfractionated and low molecular weight heparins (LMWH) for years, non-hemorrhagic effects (osteoporosis, reduction of elevated blood pressure, with lesser intra- and interdialytic hypotensive episodes, effects on brain microvascular circulation and decreasing vascular dementia and Alzheimer’s disease, and chronic and malignant diseases) require new trials with individualized doses of heparins

Ključne riječi

anticoagulation; low molecular weight heparin; hemodialysis

Hrčak ID:

97570

URI

https://hrcak.srce.hr/97570

Datum izdavanja:

14.2.2013.

Podaci na drugim jezicima: hrvatski

Posjeta: 3.471 *